How do Emgality and Ajovy work?
Emgality (galcanezumab) and Ajovy (fremanezumab) are both CGRP monoclonal antibodies that prevent migraines by blocking calcitonin gene-related peptide, a protein involved in migraine attacks. Emgality is monthly; Ajovy offers monthly or quarterly dosing.[1]
What do clinical trials show for effectiveness?
Phase 3 trials (e.g., EVOLVE-1/2 for Emgality, HALO for Ajovy) found both reduce monthly migraine days by 4-5 days on average in episodic migraine patients after 3-6 months. Emgality showed 50% response rates (≥50% reduction) in 39-41% of patients; Ajovy in 38-42%. No head-to-head trials exist, so neither proves superior. Real-world data varies, with some patients preferring one based on individual response.[1][2]
Which has better tolerability and side effects?
Both have similar profiles: injection-site reactions (15-45%), constipation (1-5%), and rare hypersensitivity. Ajovy reports slightly higher injection-site pain (43% vs. Emgality's 18-28%). Discontinuation rates due to adverse events are low and comparable (~1-5%). Neither affects blood pressure or cognition significantly.[1][2]
How do dosing and convenience compare?
Emgality requires one monthly subcutaneous injection (120 mg after 240 mg loading dose). Ajovy is 225 mg monthly or three 225 mg quarterly. Quarterly Ajovy appeals to those avoiding frequent shots, but startup requires three injections.[1]
What's the cost and insurance coverage like?
List prices are similar (~$800-900/month), but copays depend on insurance. Patient assistance programs exist for both. No clear cost winner; generics unavailable as both are biologics.3
Patient experiences and when to choose one over the other?
Switching occurs if one fails after 2-3 months; ~30-50% respond to second CGRP if first fails. Emgality may edge cluster headaches (FDA-approved); Ajovy lacks this. Consult neurologists—response is highly individual. Track via apps like Migraine Buddy.[1][2]
[1]: FDA labels via Drugs@FDA (emgality.com, ajovy.com)
[2]: Clinical trials on PubMed (e.g., Lancet Neurol 2018 for Ajovy; NEJM 2017 for Emgality)